Suflave

Suflave is an osmotic laxative indicated for the cleansing of the colon as a preparation for colonoscopy in adults. Developed by Braintree Laboratories (a subsidiary of Sebela Pharmaceuticals), it is a low-volume bowel preparation kit consisting of two bottles, each containing a powder blend of polyethylene glycol 3350, sodium sulfate, magnesium sulfate, potassium chloride, and sodium chloride. When reconstituted with water, it forms a lemon-lime flavored solution. The mechanism of action relies on the osmotic properties of its constituents; the sulfate salts and PEG 3350 are poorly absorbed and create an osmotic gradient that retains water within the intestinal lumen. This increases stool volume and promotes bowel evacuation. Suflave was FDA-approved in 2023 and was designed to provide a more palatable alternative to traditional high-volume PEG-based preparations, aiming to improve patient adherence and the quality of colon cleansing.

Brand names

Suflave

Other names

polyethylene glycol 3350 + sodium sulfate + magnesium sulfate + potassium chloride + sodium chloride